NASDAQ: ANTX · Life Sciences · 3 alerts · CIK 1880438
Share price
$4.47Close, Nov 16
Market cap
$170M
Shares outstanding
37.94MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All AN2 Therapeutics, Inc. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, AN2 Therapeutics reported a net loss of $26.2 million, a slight improvement from the $26.5 million loss in the prior year. Total assets increased to $82.0 million from $62.0 million at year-end 2025, primarily driven by an increase in short-term and long-term investments following a private placement of common stock.
AN2 Therapeutics reported financial results for the third quarter of 2026, highlighting a net loss of $11.4 million and a cash position of $51.4 million. The company is advancing its clinical pipeline, including the expected year-end enrollment initiation for its Phase 2 study of epetraborole in polycythemia vera and the selection of a new development candidate for hypophosphatasia.
Term
Q3 2026
“The third quarter was marked by continued execution across our clinical pipeline and meaningful progress in expanding the opportunities enabled by our boron chemistry platform. With FDA IND clearance for epetraborole in polycythemia vera, we now have the necessary regulatory clearances from all planned jurisdictions for our global Phase 2 study and are advancing start up activities.”
Eric Easom, Co-Founder, Chairman, President and CEO
“Beyond our clinical stage pipeline, the selection of AN2-504661 for HPP as our second development candidate this year, further demonstrates the productivity of our research organization and the potential of our boron chemistry platform to generate differentiated therapies across multiple disease areas.”
Eric Easom, Co-Founder, Chairman, President and CEO
AN2 Therapeutics Insider Joshua M. Eizen Sells $11.9K of Stock
Joshua M. Eizen sold 2,826 shares of AN2 Therapeutics, Inc. at $4.22 a share, worth $11.9K in total on Nov 5, 2026. Shares held after the trade: 207,546 (-1.3%).